Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2014-07-09 Regulatory Filings
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the authorization to launch a Phase IIa clinical study for a drug candidate (HinsBet®). It details the study design, objectives, regulatory approval (from BfArM), and expected timelines. This type of announcement, focusing on clinical trial progress and regulatory milestones for a specific product, is characteristic of corporate communications in the pharmaceutical/biotech sector. It is not a full Annual Report (10-K), a formal Audit Report (AR), a Dividend Notice (DIV), or a standard Earnings Release (ER) which focuses purely on financial figures. Since it is a specific announcement about clinical development and regulatory progress, it fits best under the general category of Regulatory Filings (RNS) as a specific press release detailing operational/clinical progress, or potentially a Capital/Financing Update (CAP) if it were tied to fundraising, but here it is purely operational/clinical news. Given the options, RNS serves as the best general category for specific, non-financial, non-governance regulatory/operational announcements that don't fit elsewhere, although 'LTR' (Legal Proceedings Report) is for lawsuits, and 'ER' is for earnings. Since this is a press release announcing a clinical trial initiation, RNS is the most appropriate fallback for a specific operational update that isn't a standard financial report.
2014-07-09 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly titled '# PRESS RELEASE' and announces the approval to start a Phase IIa clinical study for a drug candidate (HinsBet®). It details the study design, objectives, timeline (First Patient In planned for August, results expected Q1 2015), and provides background information on the disease and the company's technology. This content structure—a formal announcement of a significant operational/clinical milestone via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a primary announcement of business progress rather than just a notice of a report publication (RPA), it fits best as an Earnings Release (ER) which often includes key operational updates alongside financial highlights, or RNS as a general regulatory announcement. Given the focus on clinical trial progress and regulatory approval, which are key operational updates often bundled with earnings, ER is a strong candidate, but RNS is the safest general regulatory announcement category if it's not tied to a specific reporting period's financials. However, many companies use press releases for major operational news outside of quarterly reporting cycles. Since this is a specific, time-sensitive operational update (clinical trial approval), and not a standard quarterly financial summary, it leans towards a general regulatory announcement or a specific operational update. Given the options, and that it's a press release announcing a major operational/regulatory event (clinical trial approval), it is best classified as a Regulatory Filing (RNS) as a broad category for non-standard, material announcements, or potentially ER if it were near a reporting date, but RNS covers general material announcements well. I will select RNS as the most appropriate general regulatory announcement type for a clinical trial approval press release.
2014-07-09 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces positive preclinical results for a drug candidate (BioChaperone® Lispro U300). It details scientific findings, compares them to existing products, quotes management, and outlines future clinical study schedules (Phase 1/2 in H1 2015). This structure is characteristic of an initial announcement of significant operational or scientific progress, which aligns best with an Earnings Release (ER) if it were financial results, or more generally, a corporate announcement. Since it is not a formal regulatory filing like a 10-K, a specific financial report (IR, MRQ), or a transcript (CT), and it is a primary announcement of company news, it fits the general category of an Earnings Release (ER) which often includes operational highlights, or the broader Regulatory Filings (RNS) if ER is too specific for non-financial results. Given the context of financial reporting databases, press releases announcing key operational milestones (like positive trial data) are often categorized alongside ERs or as general Regulatory Filings (RNS). Since this is a major operational update, and not a formal financial report, RNS is the most appropriate fallback for a non-standard announcement, although ER is sometimes used broadly for major company updates. However, since it is not reporting *financial* earnings, RNS is safer, or potentially IP if it were a presentation, but it is a press release. I will classify this as a general Regulatory Filing (RNS) as it is a broad press release announcing corporate news that doesn't fit the other specific categories like DIV, CAP, or MANG.
2014-06-10 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces positive preclinical results for a new insulin formulation (BioChaperone® Lispro U300). It details scientific findings, compares them to existing products, quotes management, and mentions future clinical trial plans (Phase 1/2 in H1 2015). This format—a formal announcement of significant operational or scientific progress, often released to the public and media—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change announcement (MANG), it fits best as an initial announcement of results/progress. Given the content focuses on scientific/product development milestones rather than just quarterly financial highlights, it leans towards a general regulatory announcement or a specific type of press release. However, in the context of financial filings, press releases announcing key operational/scientific progress are often categorized as Earnings Releases (ER) if they relate to performance, or RNS if they are general news. Since this is a major scientific update with future financial implications, and it is not a formal quarterly/annual report, it is classified as a general Regulatory Filing (RNS) as it is a broad announcement not covered by the more specific codes like ER (which usually focuses on P&L/Balance Sheet highlights). The length (11k chars) is substantial, ruling out a simple RPA.
2014-06-10 French
Communiqués en période d’offre / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that Adocia will present positive clinical results for its BioChaperone® products at the 74th Scientific Sessions of the American Diabetes Association (ADA) on June 15, 2014. It details the content of the posters to be presented (Phase II clinical data for BioChaperone Lispro and BioChaperone Combo) and provides background information on the conference and the products. This is a communication intended to inform the public and investors about upcoming scientific presentations and data releases, rather than being the full financial report (10-K, IR), a formal earnings announcement (ER), or a transcript (CT). Since it is an announcement about presenting clinical data at a scientific conference, it functions as a general corporate update or news release. Given the options, it is best classified as a general Regulatory Filing (RNS) as it is a press release detailing corporate scientific progress, or potentially an Investor Presentation (IP) if it were the slides themselves, but as a press release announcing the presentation, RNS is the most appropriate general category for non-standard announcements, or potentially ER if it were tied to a specific reporting period, but here it is focused on scientific data presentation. Since it is a press release announcing scientific data presentation, and not a formal earnings release or a specific regulatory filing like DIRS or DIV, RNS (Regulatory Filings / General regulatory announcements) serves as the best fit among the provided codes for a general corporate news announcement.
2014-06-04 French
Communications during bidding periods / Other releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'PRESS RELEASE' and announces that Adocia will present successful clinical results at the American Diabetes Association (ADA) 74th Scientific Sessions. It details the specific posters (78-LB and 83-LB) and the dates/times of the presentations (June 15th, 2014). This is not a full financial report (10-K or IR), nor is it a formal earnings release (ER) which typically focuses on P&L/Balance Sheet figures. It is an announcement about upcoming scientific/clinical data presentation, which falls under general investor/corporate news. Since it is a press release announcing scientific data presentation rather than a formal regulatory filing or a specific financial report, the most appropriate category is 'Regulatory Filings' (RNS) as a general announcement/news release, although 'Investor Presentation' (IP) is related to the content, the document itself is the announcement of the presentation, not the presentation slides themselves. Given the options, RNS serves as the best general category for corporate news releases that don't fit the highly specific financial/governance codes.
2014-06-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.